학술 및 논문 자료 31

1. Author(year): Alberto Aimo et al. (2016)

2. Study: Meta analysis

3. Population: Chronic HF out patients

4. Study description: Seven studies were included(4 reporting HR and 95% CI values in the published paper and 3 after the authors consent to provide unpublished data

5. N: 6372

6. Average age(year): 65

7. Average LVEF(%): 29.1

8. Primary outcome: 

9. Follow-up duration: 

10. Summary of findings: sST2 is a predictor of both all-cause and CV death in CHF outpatients, further supporting current American College of Cardiology Foundation/American Heart Association recommendations, which have indicated that sST2 assay is a valuable tool for risk stratification in this setting.

11. Link: https://www.sciencedirect.com/science/article/pii/S2213177916304966

1. Author(year): Antoni Bayes-Genis et al. (2015)

2. Study: PROTECT

3. Population: Ambulatory heart failure

4. Study description: Examined biomarkers representative of multiple pathogenic pathways: soluble ST2, NT-proBNP, hsCRP, galectin-3, hsTnT

5. N: 1015

6. Average age(year): 67.3

7. Average LVEF(%): 33.5

8. Primary outcome: Cardiac trasplant or left ventricular assist device implant

9. Follow-up duration: 4.2 ± 2.1 years

10. Summary of findings: ST2 provides long-term risk stratification information in HF at different serum concentrations of other biomarkers that reflect stretch, inflammation, necrosis, and remodeling

11. Link: https://www.sciencedirect.com/science/article/abs/pii/S107191641401269X

1. Author(year): Anand et al. (2014)

2. Study: San Diego, CA

3. Population: Patients with NYHA class II-IV HF

4. Study description: Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial

5. N: 1650

6. Average age(year): 

7. Average LVEF(%): ‹40%

8. Primary outcome: 

9. Follow-up duration: 4 months, and 12 months

10. Summary of findings: Baseline sST2 was nonlinearly associated with patient outcomes, but didn’t provide substantial prognostic information when added to a clinical prediction model that included NT-proBNP. An increase but not decrease in sST2 was independently associated with outcomes.

11. Link: https://www.ahajournals.org/doi/full/10.1161/CIRCHEARTFAILURE.113.001036

1. Author(year): Wojtczak-Soska K et al. (2014)

2. Study: 

3. Population: Patients with CHF in the stable I-III NYHA class

4. Study description: Soluble ST2 protein in the short-term prognosis after hospitalization in chronic systolic heart failure

5. N: 167

6. Average age(year): 62

7. Average LVEF(%): ‹45%

8. Primary outcome: 

9. Follow-up duration: 1 year

10. Summary of findings: Inpatients with CHF with LVEF ‹45% the prognostic value of sST2 protein in the short-term observation of one year was confirmed. sST2 protein was an independent variable for the composite end point, which consisted of worsening in NYHA functional class, hospitalization for worsening of heart failure, the need to increase the dose of diuretics and/or death

11. Link: https://journals.viamedica.pl/kardiologia_polska/article/view/KP.a2014.0085/57205

1. Author(year): Januzzi et al. (2014)

2. Study: 

3. Population: Patients with chronic HF due to left ventricular systolic dysfunction

4. Study description: High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure

5. N: 1141

6. Average age(year): 

7. Average LVEF(%): 

8. Primary outcome: Death

9. Follow-up duration: 2.8 years

10. Summary of findings: ST2 is a potent marker of risk in chronic heart failure and when used in combination with NT-proBNP offers moderate improvement in assessing prognosis beyond clinical risk scores.

11. Link: https://www.sciencedirect.com/science/article/pii/S2213177913004137

1. Author(year): Sobczak S et al. (2014)

2. Study: Pol Arch Med Wewn

3. Population: Patients with chronic heart failure.

4. Study description: Single ST2 protein measurement predicts adverse outcomes at 1-year follow-up in patients with chronic heart failure

5. N: 145

6. Average age(year): 62.16±11.25

7. Average LVEF(%): ≤30%

8. Primary outcome: 

9. Follow-up duration: 1 year

10. Summary of findings: Single measurement of sST2 in patients with poor LV systolic function and stable CHF is useful in short-term risk stratification and in combination with NT-proBNP could be used to better identification of the high-risk population unfavorable course of CHF.

11. Link: https://web.archive.org/web/20180721005005id_/http://pamw.pl/sites/default/files/54_Lelonek%20online.pdf

1. Author(year): Karolina et al. (2012)

2. Study: Poland

3. Population: Patients in stable NYHA class I - II

4. Study description: Soluble ST2 protein in chronic heart failure is independent of traditional factor

5. N: 66

6. Average age(year): 62

7. Average LVEF(%): ‹45%

8. Primary outcome: 

9. Follow-up duration: 

10. Summary of findings: sST2 protein is independent of traditional factors which usually affect levels of NT-proBNP 

11. Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598130/


1. Author(year): Bonnie Ky et al. (2011)

2. Study: 

3. Population: Chronic heart failure out-patients

4. Study description: High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure

5. N: 1141

6. Average age(year): 

7. Average LVEF(%): 

8. Primary outcome: Death

9. Follow-up duration: 2.8 years

10. Summary of findings: ST2 is a potent marker of risk in chronic heart failure and when used in combination with NT-proBNP offers moderate improvement in assessing prognosis beyond clinical risk scores.

11. Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163169/

1. Author(year): Pascual Figal et al. (2009)

2. Study: MUSIC

3. Population: Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction

4. Study description: Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic heart Failure and Left Ventricular Systolic Dysfunction

5. N: 99

6. Average age(year): 

7. Average LVEF(%): ≤45%

8. Primary outcome: Death, HF admission cardiac transplant

9. Follow-up duration: 

10. Summary of findings: Elevated sST2 concentrations are predictive of SCD in patients with chronic HF and provide complementary information to NT-proBNP levels.

11. Link: https://www.jacc.org/doi/pdf/10.1016/j.jacc.2009.07.041

1. Author(year): Felker et al. (2013)

2. Study: HF-Action

3. Population: Ambulatory HF

4. Study description: Association of ST2 with functional capacity and clinical outcomes

5. N: 912

6. Average age(year): 59

7. Average LVEF(%): ‹35

8. Primary outcome: Functional capacity; death or hospitalization

9. Follow-up duration: 2.5 years

10. Summary of findings: ST2 levels modestly associated with functional capacity, and associated with worse outcomes

11. Link: https://www.ahajournals.org/doi/epub/10.1161/CIRCHEARTFAILURE.113.000207